NEW YORK (GenomeWeb News) – Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma plan to develop and market a diagnostic tool to rapidly diagnose patients who have lipoprotein lipase deficiency (LPLD) and may be candidates for an AMT therapeutic.

AMT said today that it will collaborate with Progenika to develop the LPLchip, which is based on Progenika's DNA-chip technology, to diagnose patients with complete and partial LPLD who may benefit from treatment with AMT's Glybera, a gene therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.